安徽割双眼皮哪里好(宜宾割双眼皮哪家医院专业) (今日更新中)

Horseshoe crabs are prehistoric creatures that predate the dinosaurs, but pharmaceutical companies depend on them to this day for their unique blue blood.The crabs’ blood is hypersensitive to endotoxins, making it the perfect testing ground to see if a coronavirus vaccine is harmful to people."The fact that we rely so much on these really primitive creatures that predate the dinosaurs," said Barbara Brummer, the state director of The Nature Conservancy in New Jersey.From Massachusetts to South Carolina, the crabs are collected and taken to laboratories. But one of their largest breeding grounds is right in New Jersey, in the Delaware Bay."The concern is the population of horseshoe crabs in the Delaware Bay has been declining over the years," said Brummer. "They are needed for the ecological value they bring for shorebirds.”Shorebirds rely on the crabs' millions of eggs for food.New Jersey fishermen are banned from using the crabs for bait. But pharmaceutical companies remove about a half-million horseshoe crabs from the ocean every year.In the labs, about one-third of a crab's blood is removed for testing. If the crab's blue blood clots up, the medicine is no good.The crabs are then returned to the ocean.However, a study by the Atlantic States Marine Fisheries Commission estimates about 15% of the crabs do not survive."There is an alternative test," Brummer said. "They have created a test that does not involve the bleeding of the crabs. It is a synthetic material."The synthetic test has been approved in Europe but has not yet been approved in the United States.This story was first reported by Christie Duffy at PIX11 in New York, New York. 1674

Grocery chain Kroger announced Tuesday that is plans to hire 1,000 people to administer coronavirus vaccines at the chain’s 2,200 pharmacies and 220 clinics.Kroger’s vaccine program launches this week in the state of Alaska as health care workers in Anchorage and Juneau will be vaccinated by Kroger staff. Kroger says that it is working with state and federal officials to vaccinate others in prioritized populations, such as health care workers, and those living and working in assisted living facilities.Kroger is not the only major company to assist in administering vaccines. CVS and Walgreens began administering vaccines to those living and working in assisted living facilities this week.“Kroger Health is a COVID-19 response leader that has provided our patients, associates and other businesses with diagnostic testing tools and supporting resources since the onset of this public health crisis,” said Colleen Lindholz, Kroger Health’s president. “Kroger Health’s experienced health care providers remain committed to helping our patients and associates live healthier lives. The size and scale of our health care operation provides us with the unique ability to efficiently facilitate COVID-19 testing and immunize a large portion of the U.S. population, once the authorized vaccines become more widely available.”There have been two coronavirus vaccines authorized by the FDA.Moderna’s vaccine has been hailed as a medical breakthrough. The vaccine has been considered 94.1% effective against the virus. According to Moderna, none of the thousands who were given two shots of the vaccine had severe COVID-19 symptoms. That is compared to 30 patients who were given a placebo who had symptoms.Pfizer’s vaccine has an effectiveness of 95%. It too comes in two shots.Those wishing to apply to assist in administering vaccines, click here. 1855

Harvard Kennedy School has rescinded its invitation to Chelsea Manning to be a visiting fellow at the school this fall, according to a statement from its dean, Douglas W. Elmendorf.Its Institute of Politics had announced on Wednesday that Manning would be one of approximately 10 visiting fellows, but the school withdrew the offer early Friday morning following controversy.Manning is still invited to spend a day at the Kennedy School and participate in a forum with students, but Elmendorf said in a statement that designating her as visiting fellow was "a mistake." 577

Hospital employees from the Naval Hospital Jacksonville have been removed from patient care after disturbing photos involving newborns went viral on Monday.The viral post, that has been shared more than 185,000 times, shows screenshots taken from the employees' Snapchat accounts. In the images, the employee is seen sticking up her middle finger to a newborn, captioned with "How I currently feel about these mini Satans." The post also explains that in one of the Snapchat screenshots, the "navy nurse" and her friend held up the baby, making the baby dance to rap music.The Naval Hospital Jacksonville posted a statement addressing the photos on their Facebook page: 702

Holidays will look different this year for many Americans, with dinners outside, social distancing, or passing on family gatherings altogether. But several companies developing rapid at-home COVID-19 tests are hopeful that won't be the case next year. The goal is to make inexpensive, easy-to-use COVID tests that can deliver results in minutes, just like a pregnancy test. "For people to feel comfortable to associate with friends or family, there needs to be a testing methodology ideally that can be performed at home," said Tony Lemmo, CEO of the manufacturing company BioDot.The company's technology is being used by over 70 manufacturers worldwide making COVID-19 antigen, antibody, and PCR tests. Their automated platforms dispense nanoliter/picoliter amounts of reagent onto the tests accurately and fast.Lemmo says just one of their systems can support the production of roughly 100 million COVID-19 tests per year, helping to make high-volume production possible.“We knew we were going to be called on by customers to manufacture more equipment to provide them the ability to manufacture more tests," said Lemmo. To meet customer demand, BioDot increased staffing and built a new facility, compressing production time from months to weeks. The FDA recently authorized the first rapid at-home test that can deliver results in 30 minutes, eliminating the need for a lab to test the sample. But the molecular single-use test will only be available to patients with a doctor's prescription who are suspected of being infected with COVID-19.Companies developing tests hope the FDA will soon authorize another at-home testing tool: the rapid antigen test.These inexpensive tests provide results within minutes, and companies developing them say millions could be sold without a doctor's referral.“From what we’re hearing, it’s really just a matter of possibly months before there’s at least sufficient data to be able to support an at-home use of a test like an antigen test," said Lemmo.Lemmo says if authorized by the FDA, manufacturers could make millions of these tests in a matter of months. But antigen tests are less accurate, and the FDA wants to ensure they'll be simple enough for people to use at home. There are also concerns over how the data will be reported to health authorities. “I think any at-home testing or massive rollout of a test into the communities needs to be done very carefully and with a lot of education around it," said Clinical Lab Director Melissa Miller. Dr. Miller is a professor of pathology and laboratory medicine at the University of North Carolina Chapel Hill and Medical Director for the Clinical Microbiology Lab for the Medical Center.She worries the inaccuracies of these tests could eventually lead the public to lose trust in all testing. “Even at 98 percent specificity, which is very, very high. That means you’re going to have a false positive two out of every 100. If you started testing a hundred million people, this is millions of people who have a false-positive test," said Dr. Miller. She says this could lead to healthy people isolating and missing work or school unnecessarily, and false-negative results could give people a false sense of security. “These rapid antigen tests were pushed out to skilled nursing facilities; this is a very high-risk patient population. This is actually where you want a very accurate test," said Dr. Miller. She says it’s unclear how well antigen tests detect the virus in asymptomatic patients but agrees more data is needed to figure that out.“It might make more sense for K-12 schools, or even college settings, where there’s less risk for a poor outcome if you have a false positive or a false negative," said Dr. Miller. But with a growing demand for convenient at-home testing, manufacturers are hopeful that in the months ahead, the FDA will soon open the door to new solutions. 3889

来源：资阳报